注射用重组Ⅱ型肿瘤坏死因子受体抗体融合蛋白联合柳氮磺吡啶治疗活动性强直性脊柱炎的疗效

Efficacy of recombinant human tumor necrosis factor receptor Ⅱ:IgG Fc fusion protein for injection combined with sulfasalazine in the treatment of active ankylosing spondylitis

目的观察注射用重组Ⅱ型肿瘤坏死因子受体抗体融合蛋白(rh TNFR:Fc)联合柳氮磺吡啶治疗活动性强直性脊柱炎(AS)的临床效果。方法选取我院诊治的70例活动性AS患者,根据随机数表法分为观察组与对照组,各35例。对照组采用柳氮磺吡啶治疗,观察组在对照组基础上联合rh TNFR:Fc治疗,比较两组治疗效果。结果治疗3、6个月后,两组的BASDAL、VAS评分、ESR、CRP水平均较治疗前显著降低,且观察组低于对照组(P<0.05)。观察组治疗有效率高于对照组(P=0.041)。两组治疗期间均无不良反应发生。结论活动性AS采用rh TNFR:Fc联合柳氮磺吡啶治疗疗效确切。

Objective To observe the clinical effect of recombinant human tumor necrosis factor receptorⅡ： IgG Fc fusion protein（rh TNFR：Fc） for injection combined with sulfasalazine in active ankylosing spondylitis（AS）. Methods Seventy patients with active AS ad mitted into our hospital were selected and divided into observation group and control group by random number table method, with 35 cases in each group. The control group was treated with sulfasalazine, while the observation group was treated with rh TNFR：Fc based on the control group. The curative effects were compared between the two groups. Results After treatment of 3, 6 months, the BASDAI, VAS scores, ESR and CRP levels in the two groups decreased, those of the observation group were lower than the control group（P〈0.05）. The total effective rate of the observation group was higher than that of the control group（P=0.041）. There was no adverse reactions in the two groups. Conclusion The rh TNFR：Fc combined with sulfasalazine in the treatment of active AS has significant effect.